2026.03.05Immunis Licenses Treatment Candidate for Dyskinesia Associated with Parkinson’s Disease

2026.02.17Cyrano Therapeutics Announces Positive Topline Results from Phase 2 FLAVOR Trial of CYR-064, a Proprietary and Potential First-to-Market Regenerative Therapy for Persistent Smell Loss

2026.01.14Immunis Announces Preliminary Results from First-Ever Phase 2 Study of a Secretome-Based Biologic Showing Improved Gait Speed in Obese Sarcopenic Seniors

2025.04.24Remiges Ventures Launches RDiscovery Fund: Incubating Drug Discovery Seeds

2025.02.18KYORIN and Cyrano Therapeutics Partner to Advance CYR-064

　　News　＞　

What Remiges Does >

Team >

Portfolio Companies >

Contact >

LP Portal >